Lipfendra (Enlicitide) Slashes LDL Cholesterol! Does It Save Lives?

The Food and Drug Administration approved a brand-new cholesterol pill on July 16, 2026. This medicine is a PCSK9 inhibitor. Unlike its comrades, alirocumab (Praluent) and evolocumab (Repatha), it is taken by mouth rather than injected. Judging from the headlines, you might think cardiologists had just discovered how to prevent heart attacks once and for all.

The Wall Street Journal announced:

“FDA Approves First-of-Its-Kind Cholesterol Pill, Ushering In New Wave of Treatment”

Fox News was even more enthusiastic:

“Game-Changing Cholesterol Pill Wins FDA Approval After Cutting LDL Nearly 60%”

Fierce Pharma declared:

“Merck Scores at FDA as Lipfendra Becomes World’s First Oral PCSK9 Treatment”

And The New York Times reported:

“The F.D.A. Approves a New Pill to Slash Cholesterol Levels”

What’s the People’s Pharmacy Perspective on Lipfendra (Enlicitide)?

There is no doubt that Lipfendra represents an impressive pharmacological accomplishment. The generic name for this medication is enlicitide. It is the first oral medicine that blocks a protein called PCSK9.

Until now, drugs that targeted PCSK9 had to be injected. They include Repatha and Praluent. Many patients dislike injections, and insurers have often made injectable PCSK9 inhibitors a bit challenging to obtain.

A once-daily pill costing $315 for a 30-day supply could make this approach available to many more people. But amid all the excitement, one essential question has received far less attention:

Does Lipfendra actually prevent heart attacks, strokes or premature deaths?

At this point, no one knows.

What Did the Lipfendra Trials Actually Prove?

The FDA approved Lipfendra on the basis of two randomized, double-blind, placebo-controlled trials involving 3,207 people. Participants had very high cholesterol (“severe hypercholesterolemia”) and were already taking the maximum statin treatment they could tolerate.

The primary endpoint was not heart attacks. It was not strokes. It was not cardiovascular death or overall mortality.

The primary endpoint was the change in LDL cholesterol after 24 weeks.

Lipfendra passed that test with flying colors. It lowered LDL cholesterol by roughly 56% to 59% compared with placebo. Keep in mind that these were high-risk patients on statins. In one trial, participants had already lowered their LDL cholesterol to 96 mg/dL and in the other to 119 mg/dL. So, the new oral PCSK9 inhibitor pushed those numbers far lower!

That is an impressive effect on a laboratory measurement. It explains why headlines describe the drug as “game-changing” and say it can “slash” LDL cholesterol.

But the FDA’s approved indication is carefully worded. Lipfendra is approved, along with diet and exercise:

“…to reduce low-density lipoprotein cholesterol (LDL-C) in adults with high cholesterol…”

The agency does not say that Lipfendra has been shown to prevent heart attacks or strokes or prolong life. That’s because the clinical outcome data are not yet available.

The pivotal CORALreef Lipids trial was published in the New England Journal of Medicine (Feb. 4, 2026). Its conclusion was also precise:

“Among participants who had a history of or were at risk for a first atherosclerotic cardiovascular disease event, treatment with the oral PCSK9 inhibitor enlicitide resulted in significantly lower LDL cholesterol levels than placebo at 24 weeks.”

It did not conclude that the drug prevented cardiovascular events. We anticipate that it will, but the effects will be in line with what we have seen with Repatha and Praluent. That could be an absolute risk reduction of around 1.5 to 2.0 percentage points.

Lipfendra Lowers LDL, But Outcomes Remain Unknown

Merck is conducting a large randomized clinical trial called CORALreef Outcomes. It is designed to determine whether enlicitide reduces the things patients really care about: heart attacks, strokes, cardiovascular deaths and other serious vascular complications. More than 14,000 patients are expected to participate. Results are anticipated in 2029.

That means doctors will likely be prescribing Lipfendra for several years before the definitive cardiovascular-outcome evidence becomes available. Merck Research Laboratories President Dr. Dean Li told The New York Times that he is confident Lipfendra will produce the same cardiovascular benefits seen with injectable PCSK9 inhibitors. He may turn out to be absolutely right. But confidence is not evidence.

That is why randomized clinical trials are conducted.

Can We Assume Lipfendra Will Prevent Heart Attacks?

There is a logical reason to expect cardiovascular benefit. Lipfendra blocks the same protein targeted by Repatha and Praluent. Those injectable PCSK9 inhibitors have been tested in large clinical-outcome trials.

In the FOURIER trial, evolocumab lowered LDL cholesterol by about 59%. It reduced the primary composite cardiovascular endpoint by approximately 15% relative to placebo. A narrower secondary endpoint consisting of cardiovascular death, heart attack or stroke was reduced by about 20%.

Relative Risk vs. Absolute Risk Reduction

Here is how I described the outcomes that people really care about:

“The FOURIER trial was published in The New England Journal of Medicine (online March 17, 2017). There were 27,564 patients at high risk for heart disease. Many had already suffered a heart attack. LDL cholesterol was aggressively lowered with a statin and Repatha. A “control” group got statins plus placebo injections instead of Repatha. LDL cholesterol levels were reduced to around 30 in the Repatha group. That’s impressive.

“The relative risk reduction after 26 months was 21 to 27 percent. But the absolute risk reduction was less than 2 percent. We are talking about heart attack, stroke or cardiovascular death. The patients who “only” got a statin experienced one of those end points 7.4% of the time. The patients who got a statin plus Repatha (evolocumab) experienced a heart attack, stroke or cardiovascular death 5.9% of the time. Do the math. The difference was 1.5%.”

The authors go a bit further:

“Overall, 74 patients would need to be treated over a period of 2 years to prevent a cardiovascular death, myocardial infarction, or stroke.”

Please reread that sentence 2 more times. I interpret it to mean that for one person to avoid a heart attack, stroke or death from cardiovascular causes, 73 other people would need to be treated with Repatha plus a statin and they would get no such benefit.

Beware Composite Outcomes

Researchers like to lump outcomes together. That is why you see above “cardiovascular death, myocardial infarction, or stroke” collected as “secondary end points.” But what if we just looked at the ultimate end point…death? The authors state:

“In terms of individual outcomes, evolocumab had no observed effect on cardiovascular mortality…no observed effect on the rates of hospitalization for unstable angina, cardiovascular death or hospitalization for worsening heart failure, or death from any cause.”

Think about that for a moment. These are high-risk patients. They got statins plus Repatha. Their LDL cholesterol levels were lowered dramatically. But, if I interpret the results correctly, no lives were saved.

What About the Odyssey?

The ODYSSEY OUTCOMES trial (New England Journal of Medicine, Nov. 7, 2018) tested alirocumab (Praluent) after acute coronary syndrome (ACS). Let me tell you that ACS is bad news! It is basically a heart attack in progress. When plaque ruptures and causes a blockage in a coronary artery, doctors often call that acute coronary syndrome.

The primary cardiovascular endpoint in the ODYSSEY OUTCOMES TRIAL was another one of those lumped-together “composites” of:

• “death from coronary heart disease
• nonfatal myocardial infarction [heart attack]
• fatal or nonfatal ischemic stroke
• unstable angina requiring hospitalization.”

That composite of bad outcomes occurred in 9.5% of patients receiving Praluent and 11.1% of those receiving placebo. That represents an absolute difference of 1.6 percentage points over a median follow-up of 2.8 years. That’s something, but it is not as if PCSK9 inhibitor drugs protect everyone or even a majority of patients from terrible cardiovascular accidents or death.

These trials provide good reason for optimism about Lipfendra (enlicitide). But they do not prove that every drug that changes cholesterol in a favorable direction will necessarily improve clinical outcomes in a dramatic fashion. Perhaps that is why heart disease remains our number one killer even after decades of highly effective medications that lower LDL cholesterol.

Medical history provides some sobering examples.

The Cholesterol Drug That Looked Almost Perfect

Evacetrapib was an experimental cholesterol medicine developed by Eli Lilly. It inhibited a protein called CETP.

On paper, the drug looked like a cardiologist’s dream. In a large randomized trial, evacetrapib:

• lowered LDL cholesterol by approximately 31%
• raised HDL cholesterol by approximately 133%

It seemed to be doing two desirable things at once: lowering “bad” cholesterol while dramatically raising “good” cholesterol.

But when more than 12,000 high-risk patients were followed in the ACCELERATE trial (New England Journal of Medicine, May 18, 2017), the beautiful cholesterol numbers did not translate into fewer cardiovascular events.

The primary endpoint occurred in:

• 12.9% of patients receiving evacetrapib
• 12.8% of patients receiving placebo

There was no significant reduction in cardiovascular death, heart attack, stroke, coronary revascularization or hospitalization for unstable angina.

The trial was stopped early because it was “futile.”

When Better Cholesterol Numbers Led to Worse Outcomes

Torcetrapib offers an even more disturbing example. This experimental CETP inhibitor increased HDL cholesterol by approximately 72% and lowered LDL cholesterol by about 25%.

Once again, the laboratory results looked terrific.

But the ILLUMINATE trial (New England Journal of Medicine, Nov. 22, 2007) was terminated prematurely. Patients receiving torcetrapib experienced more cardiovascular events and more deaths than those receiving atorvastatin alone.

Major cardiovascular events occurred in:

• 6.2% of the torcetrapib group
• 5.0% of the control group

Deaths from all causes occurred in:

• 1.2% of the torcetrapib group
• 0.8% of the control group

That amounted to a 25% relative increase in major cardiovascular events and a 58% relative increase in mortality.

Torcetrapib also raised blood pressure and altered aldosterone and electrolyte levels. Investigators concluded that harmful effects peculiar to the drug may have counteracted any benefit from its impact on cholesterol.

Neither evacetrapib nor torcetrapib was approved by the FDA.

These drugs did not work the same way as enlicitide. Their failures do not mean Lipfendra will fail. We fully expect that Lipfendra will work as well as the injectable drugs, Praluent and Repatha.

But they do demonstrate why we will wait for actual clinical trial results for outcomes that people care about: heart attacks, strokes and death. Biomarkers are not the same as clinical outcomes that patients care about. Lowering a biomarker is not the same thing as helping a patient.

Did Statins Really Fail to Lower LDL Enough?

The New York Times reported that Lipfendra can bring LDL levels “far below what can be achieved with statins.” That wording may leave readers with the impression that Lipfendra was compared directly with statins and proved vastly superior.

That is not how the pivotal trial was designed.

Most participants were already taking statins or other cholesterol-lowering treatment. Enlicitide was generally tested as an addition to background therapy. The comparison was enlicitide versus placebo on top of statin treatment.

Consequently, the trial showed what Lipfendra can accomplish when added to existing therapy. It did not establish that the pill should replace statins or that statins cannot achieve very low LDL levels in some patients.

Statins also have something Lipfendra does not yet possess: decades of evidence showing reductions in heart attacks, strokes and cardiovascular mortality in appropriately selected patients. We have, however, reported that the maker of the most frequently prescribed statin, atorvastatin (Lipitor), has described the benefit this way:

“…in a large clinical study 3% of patients taking a sugar pill or placebo had a heart attack compared to 2% of patients taking Lipitor.”

Is Lipfendra Really “Just as Effective” as the Injections?

News reports repeatedly say that Lipfendra is as effective as injectable PCSK9 inhibitors. That statement is reasonable if “effective” means lowering LDL cholesterol. Enlicitide and the injectable antibodies can all reduce LDL by roughly 50% to 60% in many patients.

It is premature if “effective” means preventing heart attacks and strokes. Repatha and Praluent have completed cardiovascular-outcome trials. Lipfendra has not.

Those are two different definitions of effectiveness, and news reports should not slide casually from one to the other.

Lipfendra Is Not Quite an Ordinary Pill

Lipfendra may be more convenient than an injection, but patients will have to follow specific directions. It should be taken in the morning on an empty stomach with water, plain coffee or plain tea. Patients must then wait at least 30 minutes before eating or drinking other beverages.

That may not sound onerous. But busy people may not want to wait 30 minutes before eating after taking Lipfendra.

What About Side Effects?

In the preapproval trials, adverse events and treatment discontinuations were generally similar in the enlicitide and placebo groups. Diarrhea and dizziness were among the reported reactions. That is reassuring.

Nevertheless, the pivotal trials included just over 3,000 patients, and the primary trial period was relatively short. Uncommon or delayed adverse reactions may not become apparent until a drug is prescribed to hundreds of thousands or millions of people. That is not an accusation against Lipfendra. It is the reality for every newly approved medication.

The People’s Pharmacy Perspective on Lipfendra

Lipfendra could become an important option for people who cannot lower LDL sufficiently with statins, ezetimibe or other treatments. It may be especially appealing to patients who dislike injections or have had difficulty obtaining injectable PCSK9 inhibitors. And people who cannot tolerate a statin often report doing well on a PCSK9 inhibitor. That could mean Lipfendra would be able to substitute for a statin in such patients.

Its LDL-lowering ability is impressive, and its mechanism provides a solid scientific reason to expect that it may eventually reduce cardiovascular events. How much it will reduce heart attacks, strokes and premature deaths remains to be determined.

Here is what we know today:

Lipfendra lowers LDL cholesterol dramatically.

And here is what we do not yet know:

Whether Lipfendra itself prevents heart attacks, strokes or premature deaths.

Calling the drug “first-of-its-kind” is accurate. Calling it “game-changing” before the cardiovascular-outcome trial is completed seems premature.

The headlines might be more helpful if they said:

FDA Approves Powerful New Cholesterol Pill, But Heart Benefits Remain Unproven

That is not as effusive. It is also closer to the evidence.

Final Words:

Did you find this article informative? No other health journalist has provided this in-depth analysis of Lipfendra. Cardiologists do not seem to embrace things like absolute risk reduction, number needed to treat or the number of people who avoid premature death with a cholesterol-lowering medication.

We wish physicians would provide accurate information about actual effectiveness whenever they prescribe any medicine. That would help patients make informed decisions about the benefits and risks of medications they are encouraged to take.

If you appreciate this kind of information, we would be grateful if you would share it with friends and family members. Please encourage them to sign up for our free newsletter. It is the only way we can continue to supply this kind of in-depth analysis of medications you read about in the headlines. Thank you for your support.